Since 1960, when Barrett and Jordan established that anticoagulation reduced the risk of death in patients with pulmonary embolism,1 heparin has been the treatment of choice for thromboembolic disease. Heparin was initially administered by intravenous bolus every 4 hours until clinical trials showed that unfractionated intravenous infusion was associated with less bleeding.2,3 Unfractionated heparin was administered by intravenous infusion and the activated partial thromboplastin time (aPTT) was monitored to maintain a level between 1.5 to 2.5 times control. It was common practice to begin treatment with a loading dose of 5000 units and 1000 units per hour of infusion. Clinical experience revealed that many patients had subtherapeutic aPTT levels for more than 24 hours and were more likely to develop recurrent thromboembolism.4,5 Today, the standard of care is to use a weight-based algorithm6 or other heparin protocols7 that quickly achieve therapeutic targets for the aPTT.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 6
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
Thromboembolism or Acute Pulmonary Embolism
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.